Menu Search
Equities

Devyser Diagnostics AB

OL0:FRA

Devyser Diagnostics AB

Actions
  • Price (EUR)8.08
  • Today's Change-0.06 / -0.74%
  • Shares traded-1.00
  • 1 Year change+18.13%
  • Beta--
Data delayed at least 15 minutes, as of May 20 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.

  • Revenue in SEK (TTM)180.50m
  • Net income in SEK-45.90m
  • Incorporated2004
  • Employees124.00
  • Location
    Devyser Diagnostics ABInstrumentvagen 19HAGERSTEN 126 53SwedenSWE
  • Phone+46 856215850
  • Websitehttps://www.devyser.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.